Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region

Results from the TREAT asia HIV observational database (TAHOD)

Sang Hoon Han, Jialun Zhou, Suneeta Saghayam, Sasheela Vanar, Nittaya Phanuphak, Yi Ming A. Chen, Thira Sirisanthana, Somnuek Sungkanuparph, Christopher K.C. Lee, Sanjay Pujari, Patrick C.K. Li, Shinichi Oka, Vonthanak Saphonn, Fujie Zhang, Tuti Parwati Merati, Matthew G. Law, Jun Yong Choi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.

Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalEndocrine Journal
Volume58
Issue number6
DOIs
Publication statusPublished - Jul 11 2011
Externally publishedYes

Fingerprint

Lipodystrophy
Stavudine
HIV
Databases
Therapeutics
Logistic Models
Zidovudine
Virus Diseases
Centers for Disease Control and Prevention (U.S.)
Protease Inhibitors
Viral Load
Coinfection
Hepatitis B virus
Hepacivirus
Acquired Immunodeficiency Syndrome
Demography
Pharmaceutical Preparations

Keywords

  • Adverse effects
  • Asia-pacific
  • Combined antiretroviral treatment
  • HIV
  • Lipodystrophy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region : Results from the TREAT asia HIV observational database (TAHOD). / Han, Sang Hoon; Zhou, Jialun; Saghayam, Suneeta; Vanar, Sasheela; Phanuphak, Nittaya; Chen, Yi Ming A.; Sirisanthana, Thira; Sungkanuparph, Somnuek; Lee, Christopher K.C.; Pujari, Sanjay; Li, Patrick C.K.; Oka, Shinichi; Saphonn, Vonthanak; Zhang, Fujie; Merati, Tuti Parwati; Law, Matthew G.; Choi, Jun Yong.

In: Endocrine Journal, Vol. 58, No. 6, 11.07.2011, p. 475-484.

Research output: Contribution to journalArticle

Han, SH, Zhou, J, Saghayam, S, Vanar, S, Phanuphak, N, Chen, YMA, Sirisanthana, T, Sungkanuparph, S, Lee, CKC, Pujari, S, Li, PCK, Oka, S, Saphonn, V, Zhang, F, Merati, TP, Law, MG & Choi, JY 2011, 'Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)', Endocrine Journal, vol. 58, no. 6, pp. 475-484. https://doi.org/10.1507/endocrj.K10E-407
Han, Sang Hoon ; Zhou, Jialun ; Saghayam, Suneeta ; Vanar, Sasheela ; Phanuphak, Nittaya ; Chen, Yi Ming A. ; Sirisanthana, Thira ; Sungkanuparph, Somnuek ; Lee, Christopher K.C. ; Pujari, Sanjay ; Li, Patrick C.K. ; Oka, Shinichi ; Saphonn, Vonthanak ; Zhang, Fujie ; Merati, Tuti Parwati ; Law, Matthew G. ; Choi, Jun Yong. / Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region : Results from the TREAT asia HIV observational database (TAHOD). In: Endocrine Journal. 2011 ; Vol. 58, No. 6. pp. 475-484.
@article{7b563da0f3b14dbf83040792151afaa8,
title = "Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)",
abstract = "The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5{\%}) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.",
keywords = "Adverse effects, Asia-pacific, Combined antiretroviral treatment, HIV, Lipodystrophy",
author = "Han, {Sang Hoon} and Jialun Zhou and Suneeta Saghayam and Sasheela Vanar and Nittaya Phanuphak and Chen, {Yi Ming A.} and Thira Sirisanthana and Somnuek Sungkanuparph and Lee, {Christopher K.C.} and Sanjay Pujari and Li, {Patrick C.K.} and Shinichi Oka and Vonthanak Saphonn and Fujie Zhang and Merati, {Tuti Parwati} and Law, {Matthew G.} and Choi, {Jun Yong}",
year = "2011",
month = "7",
day = "11",
doi = "10.1507/endocrj.K10E-407",
language = "English",
volume = "58",
pages = "475--484",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region

T2 - Results from the TREAT asia HIV observational database (TAHOD)

AU - Han, Sang Hoon

AU - Zhou, Jialun

AU - Saghayam, Suneeta

AU - Vanar, Sasheela

AU - Phanuphak, Nittaya

AU - Chen, Yi Ming A.

AU - Sirisanthana, Thira

AU - Sungkanuparph, Somnuek

AU - Lee, Christopher K.C.

AU - Pujari, Sanjay

AU - Li, Patrick C.K.

AU - Oka, Shinichi

AU - Saphonn, Vonthanak

AU - Zhang, Fujie

AU - Merati, Tuti Parwati

AU - Law, Matthew G.

AU - Choi, Jun Yong

PY - 2011/7/11

Y1 - 2011/7/11

N2 - The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.

AB - The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.

KW - Adverse effects

KW - Asia-pacific

KW - Combined antiretroviral treatment

KW - HIV

KW - Lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=79959944286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959944286&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K10E-407

DO - 10.1507/endocrj.K10E-407

M3 - Article

VL - 58

SP - 475

EP - 484

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 6

ER -